Benutzerspezifische Werkzeuge

Multicentre Studies

KFO252_long

Dresden represents a specialist centre with focused pockets of high technology and basic expertise combined with the necessary clinical expertise for research and care of patients with adrenal disorders. At the same time, there are significant synergistic collaborations on adrenal-related disorders with other centres within and outside Germany. Dresden participates in several networks of adrenal-related clinical research at both national and international levels, in some cases providing leadership roles. The European Network for the Study of Adrenal Tumours ( ENS@T ) represents one highly successful example. In one collaborative effort headed by Prof. Felix Beuschlein (Munich) that arose from this network, a European-wide multi-centre project on new therapies for adrenal cortical cancer and malignant phaeochromocytoma recently received funding under the European Union Seventh Framework Programme (FP7). As part of this effort, Dresden is the participating centre to which samples for biomarker analysis will be sent for analyses to assess therapeutic efficacy with Prof. Eisenhofer acting as the European coordinator for the associated clinical trial First randomized study of malignant progressive pheochromocytoma and paraganglioma ( FIRSTMAPPP ) .

Members of Dresden CRU (Bornstein, Willenberg) have also been participating in the European multicenter study on adrenal cancer First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment ( FIRM-ACT ) headed by the Würzburg Centre. Furthermore, several investigators involved in the current initiative are also founding members of the Phaeochromocytoma Research Support Organization ( PRESSOR ) , established in 2003 as part of a combined NIH and Cold Spring Harbour initiative, aimed at improved therapies for malignant chromaffin cell tumours. As part of this effort Dresden-based investigators maintain close and strong collaborations with scientists at the NIH and other participating centres belonging to this international research network.

ENS@T-based efforts related to the FP7 award and the currently proposed CRU include the setting up of a Virtual Research Environment (VRE) that covers patient registries for different adrenal tumour disease entities. These registries serve not only as repositories for comprehensive collection of patient data but also to facilitate biobanking of related human materials (i.e. tissue, plasma, urine) for subsequent studies at the bench.

Under Prof. Eisenhofer, Dresden is leading the way in the above efforts by establishing SOPs and electronic Case Report Forms (eCRFs) for the Prospective Monoamine-Producing Tumour (PMT) study that includes centres throughout Germany and Europe.

More information you will find under menu item " Information and Links ".